{"id":"NCT02555215","sponsor":"Biogen","briefTitle":"Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)","officialTitle":"A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-22","primaryCompletion":"2018-09-24","completion":"2018-09-24","firstPosted":"2015-09-21","resultsPosted":"2019-11-22","lastUpdate":"2019-11-22"},"enrollment":20,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"DRUG","name":"dimethyl fumarate","otherNames":["DMF","BG00012"]}],"arms":[{"label":"dimethyl fumarate","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200). Secondary objectives are as follows: To evaluate the long-term efficacy of BG00012 and to describe the long-term Multiple Sclerosis (MS) outcomes in subjects who completed Study 109MS202 (NCT02410200).","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Baseline to Week 96","effectByArm":[{"arm":"Dimethyl Fumarate","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":12,"countries":["United States","Belgium","Bulgaria","Czechia","Germany","Kuwait","Latvia","Lebanon","Poland","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["Flushing","Multiple sclerosis relapse","Abdominal pain","Upper respiratory tract infection","Viral upper respiratory tract infection"]}}